Antiviral Drugs Industry - Regional Synopsis
North America Market Analysis
North America in the antiviral drugs market is anticipated to be the dominant region with the highest share of 46.8%, growing at a rate of 5.5% by the end of 2037. The region’s dominance highly depends on the U.S. market, accounting for almost 90.5% of regional sales, which is attributed to the presence of strong governmental procurement programs, progressive research and development, and an increase in healthcare spending. Besides, in 2024, the NIH made an investment of USD 4.1 billion in next-generation antivirals, which mainly includes mRNA-based therapy services that have accelerated innovation. Meanwhile, Canada’s 11% contribution also positively drives the market in the region.
The antiviral drugs market in the U.S. is dominating the overall region with a market share of 43%, effectively facilitated by expansions in Medicaid or Medicare services and federal pandemic preparedness expenditure. For instance, the HIV PrEP coverage has reached across 88% of eligible patients under Medicaid, which has bolstered Gilead’s descovy sales by almost 18.5%. Meanwhile, the NIH allocated a fund of USD 3.9 billion in pan-viral research and development, further accelerating mRNA-specific antivirals. Therefore, all these factors are highly responsible for uplifting the market in the country.
The antiviral drugs market in Canada is continuously growing at a 5.7% rate, attributed to the existence of provincial elimination programs for hepatitis C, along with universal health and medical coverage solutions. Currently, Ontario is leading with an increase in spending by 18.5% between 2021 and 2024, which has strengthened DAA accessibility to almost 200,150 patients. Besides, the PHAC’s USD 3.7 billion budget has readily prioritized influenza antivirals, of which 92% coverage is under public formulations, thereby creating an optimistic outlook for the market development in the country.
Europe Market Statistics
Europe in the antiviral drugs market is expected to be the fastest-growing region with a share of 31.7% in the market during the forecast period. The market’s upliftment in the region is propelled by a surge in the aging population, healthcare coverage policies, and regulatory reforms. For example, the 2024 Critical Medicines Act in the EU has mandated a 6.5-month antiviral stockpile, which has boosted procurement by €2.6 billion yearly. Germany is deliberately leading in per capita spending, accounting for €4.5 billion as of 2024, while the UK’s NHS has readily prioritized affordable generics with an 8.2% budget provision.
The antiviral drugs market in Germany is gaining increased exposure with 33.5% of the overall region’s market share by maintaining its dominance through tactical stockpiling policies and high medical spending. Besides, the Federal Ministry of Health’s Pandemic Preparedness Plan has successfully mandated a 25% yearly increase in antiviral reserves, further prioritizing influenza and RSV therapies. According to an article published by BMG in 2024, an estimated 23.5% of the domestic population is more than 65 years of age, which has driven the need for hepatitis B and herpes zoster treatments, with 97.5% coverage under public insurance, thus suitable for market growth.
The antiviral drugs market in the UK is significantly growing since the country holds 25.8% of the regional market share, effectively fueled by PrEP expansion, along with the NHS’s value-based procurement. Besides, an estimated 8.5% of the NHS budget has been provided to antivirals, with generic DAAs catering to 95.5% of hepatitis C patients. In addition, the 2024 ABPI article reported that there has been a surge in long-acting HIV injectables by approximately 15.9%, effectively aided by NICE’s cost-per-QALY thresholds, thereby positively impacting the market upliftment.
